Spots Global Cancer Trial Database for An Investigational Immuno-therapy Study to Investigate the Safety and Effectiveness of Nivolumab, and Nivolumab Combination Therapy in Virus-associated Tumors
The following info and data is provided "as is" to help patients around the globe.
We do not endorse or review these studies in any way.
Trial Identification
Brief Title: An Investigational Immuno-therapy Study to Investigate the Safety and Effectiveness of Nivolumab, and Nivolumab Combination Therapy in Virus-associated Tumors
Official Title: Non-Comparative, Open-Label, Multiple Cohort, Phase 1/2 Study of Nivolumab Monotherapy and Nivolumab Combination Therapy in Subjects With Virus-Positive and Virus-Negative Solid Tumors
Study ID: NCT02488759
Conditions
Study Description
Brief Summary: The purpose of this study to investigate the safety and effectiveness of nivolumab, and nivolumab combination therapy, to treat patients who have virus-associated tumors. Certain viruses have been known to play a role in tumor formation and growth. This study will investigate the effects of the study drugs, in patients who have the following types of tumors: * Anal canal cancer-No longer enrolling this tumor type * Cervical cancer * Epstein Barr Virus (EBV) positive gastric cancer-No longer enrolling this tumor type * Merkel Cell Cancer * Penile cancer-No longer enrolling this tumor type * Vaginal and vulvar cancer-No longer enrolling this tumor type * Nasopharyngeal Cancer - No longer enrolling this tumor type * Head and Neck Cancer - No longer enrolling this tumor type
Detailed Description:
Keywords
Eligibility
Minimum Age: 18 Years
Eligible Ages: ADULT, OLDER_ADULT
Sex: ALL
Healthy Volunteers: No
Locations
Local Institution - 0033, Tampa, Florida, United States
Local Institution - 0003, Atlanta, Georgia, United States
Local Institution - 0023, Lutherville, Maryland, United States
Local Institution - 0002, Boston, Massachusetts, United States
Local Institution - 0019, Boston, Massachusetts, United States
Local Institution - 0020, Boston, Massachusetts, United States
Local Institution - 0035, Ann Arbor, Michigan, United States
Local Institution - 0036, New York, New York, United States
Local Institution - 0022, Charlotte, North Carolina, United States
Local Institution - 0005, Oklahoma City, Oklahoma, United States
Local Institution - 0004, Portland, Oregon, United States
Local Institution - 0029, Pittsburgh, Pennsylvania, United States
Local Institution - 0001, Sioux Falls, South Dakota, United States
Local Institution - 0021, Seattle, Washington, United States
Local Institution - 0012, Brussels, , Belgium
Local Institution - 0014, Brussels, , Belgium
Local Institution - 0013, Bruxelles, , Belgium
Local Institution - 0031, Marseille Cedex 9, , France
Local Institution - 0038, Paris, , France
Local Institution - 0032, Toulouse Cedex 9, , France
Local Institution - 0030, Vlllejuif, , France
Local Institution - 0027, Essen, , Germany
Local Institution - 0028, Heilbronn, , Germany
Local Institution - 0039, Kashiwa-shi, Chiba, Japan
Local Institution - 0040, Chuo-ku, Tokyo, Japan
Local Institution - 0041, Koto-ku, Tokyo, Japan
Local Institution - 0024, Seoul, , Korea, Republic of
Local Institution - 0056, Mexico City, Distrito Federal, Mexico
Local Institution, Oaxaca de Juarez, Oaxaca, Mexico
Local Institution - 0046, Merida, Yucatan, Mexico
Local Institution - 0011, Amsterdam, , Netherlands
Local Institution - 0034, Utrecht, , Netherlands
Local Institution - 0018, Barcelona, , Spain
Local Institution - 0017, Madrid, , Spain
Local Institution - 0016, Navarra, , Spain
Local Institution - 0037, Tainan, , Taiwan
Local Institution - 0026, Taipei, , Taiwan
Local Institution - 0006, Glasgow, Lanarkshire, United Kingdom
Local Institution - 0010, Birmingham, West Midlands, United Kingdom
Local Institution - 0008, London, , United Kingdom
Contact Details
Name: Bristol-Myers Squibb
Affiliation: Bristol-Myers Squibb
Role: STUDY_DIRECTOR
Take Control of Your Skin and Body Changes Today.
Try out Spots for free, set up only takes 2 mins.
Join others from around the world:
